Frontiers in Clinical Drug Research: HIV

Frontiers in Clinical Drug Research: HIV

Volume: 4

Indexed in: Scopus, EBSCO.

Frontiers in Clinical Drug Research – HIV is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

The Development and Clinical Progress on Chemokine Receptor-Based HIV Entry Inhibitors

Pp. 105-137 (33)

Yi-Qun Kuang


Entry of HIV-1 into targeted host cells is a highly ordered multistage process involving first-receptor attachment, co-receptor binding, and membrane fusion. In this chapter, I will present an overview of progress on HIV-1 entry inhibitors with a focus on chemokine receptor-based antagonists. This chapter, at first, will describe the working mechanisms of chemokine receptors, HIV-1 co-receptors CCR5 and CXCR4, during the replication procedure. Then, the antagonists-based on different mechanisms will be presented in detail. At last, it will summarize and explain the distinct promising entry inhibitors based on co-receptors-interacting proteins, which is inspired by our current work.


AIDS, CCR5, Chemokine receptor, Co-receptor, CXCR4, Entry inhibitor, HIV.


Center for Translational Medicine, Huaihe Clinical College, Huaihe Hospital of Henan University, Kaifeng, Henan, China.